ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?

Key Takeaways ANIP shares are up 53% YTD on strong Q3 results and higher full-year 2025 guidance.Rare disease sales jumped over 100% Y/Y, led by surging demand for Cortrophin Gel.Generics rose 27% Y/Y, though Q4 will face tougher competition and lower volumes.Shares of ANI Pharmaceuticals (ANIP) have surged 53% so far this year compared with the industry’s 15% growth. The stock has also outperformed the sector and the S&P 500 during the same period, as shown in the chart below.ANIP Stock Outperforms Industr ...